New drug approved for relapsing remitting MS in England and Wales

29 April 2022

Vumerity (diroximel fumarate) approved for relapsing remitting MS in England and Wales

The MS Trust have recently reported that Vumerity (diroximel fumarate) has been approved by NICE (National Institute for Health and Care Excellence) for people with active relapsing remitting multiple sclerosis.

NICE has recommended that Vumerity can be prescribed as a twice daily tablet for people with relapsing remitting MS who are having relapses or have MRI evidence of MS activity.

This is excellent news. Vumerity is as effective as Tecfidera but has fewer stomach problems, meaning you can take it with a meal or on an empty stomach. An effective treatment that fits into your daily routines means you can live a life with MS that is not defined by MS.

For full details on this news, visit the MS Trust website by clicking here.

 

Blog categories: 

Category

Archive